Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
-
Published:2021-03
Issue:
Volume:145
Page:183-193
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Ito KentaroORCID, Yamanaka Takeharu, Hayashi HidetoshiORCID, Hattori Yoshihiro, Nishino KazumiORCID, Kobayashi Haruki, Oya Yuko, Yokoyama Toshihide, Seto Takashi, Azuma Koichi, Fukui Tomoya, Kozuki ToshiyukiORCID, Nakamura Atsushi, Tanaka Kentaro, Hirano Katsuya, Yokoi TakashiORCID, Daga Haruko, Sakata Shinya, Fujimoto Daichi, Mori Masahide, Maeno KenORCID, Aoki TakuyaORCID, Tamura AtsuhisaORCID, Miura SatoruORCID, Watanabe SatoshiORCID, Akamatsu Hiroaki, Hataji Osamu, Suzuki Kensuke, Hontsu Shigeto, Azuma Koji, Bessho Akihiro, Kubo Akihito, Okuno Motoyasu, Nakagawa Kazuhiko, Yamamoto NobuyukiORCID
Subject
Cancer Research,Oncology
Reference18 articles.
1. NCCN guidelines insights: non-small cell lung cancer, version 5.2018;Ettinger;J Natl Compr Canc Netw : J Natl Compr Canc Netw,2018 2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol : official journal of the European Society for Medical Oncology,2019 3. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014 4. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial;Shaw;Lancet Oncol,2016 5. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study;Seto;Lancet Oncol,2013
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|